UPDATE: COVID-19 Read the Message

Press Releases

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Date Title and Summary View
Oct 28, 2020
SOUTH PLAINFIELD, N.J. , Oct. 28, 2020 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on October 23, 2020 it approved non-statutory stock options to purchase an aggregate of 18,610 shares of its common stock and 6,860 restricted stock units ("RSUs"), each representing
Additional Formats
Oct 28, 2020
SOUTH PLAINFIELD, N.J. , Oct. 28, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences: Credit Suisse 29 th Annual Virtual Healthcare Conference Wednesday, November 11 th at 9:30 a.m.
Additional Formats
Oct 26, 2020
- Global Phase 2/3 trial now enrolling patients with highly morbid unmet medical condition - SOUTH PLAINFIELD, N.J. , Oct. 26, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT), today announced the initiation of a registration-directed Phase 2/3 clinical trial to evaluate vatiquinone
Additional Formats
Oct 22, 2020
- Massachusetts signs proclamation declaring Oct.23 as AADC Deficiency Awareness Day -   - PTC hosts Facebook Live event featuring leaders from AADC Family Network, MassBio, and Boston Children's Hospital - SOUTH PLAINFIELD, N.J. , Oct. 22, 2020 /PRNewswire/ --  PTC Therapeutics, Inc.
Additional Formats
Oct 21, 2020
- Broad approval in Brazil based on data from multiple pivotal trials -   - NDA filed with Japan's MHLW under Priority Review; Milestone triggers $7.5M payment from Roche - SOUTH PLAINFIELD, N.J. , Oct. 21, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Evrysdi™
Additional Formats
Oct 15, 2020
SOUTH PLAINFIELD, N.J. , Oct. 15, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its third quarter 2020 financial results and provide an update on the company's business and outlook on Thursday, October 29,
Additional Formats
Sep 28, 2020
- Patients in Part 1 of the FIREFISH study demonstrated gains in motor milestones between months 12 and 24 -   - Strong Evrysdi™ launch following approval with broad label - SOUTH PLAINFIELD, N.J. , Sept. 28, 2020 /PRNewswire/ --  PTC Therapeutics, Inc.
Additional Formats
Sep 25, 2020
SOUTH PLAINFIELD, N.J. , Sept. 25, 2020 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on September 21, 2020 it approved non-statutory stock options to purchase an aggregate of 75,670 shares of its common stock and 12,845 restricted stock units ("RSUs"), each
Additional Formats
Sep 24, 2020
SOUTH PLAINFIELD, N.J. , Sept. 24, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the Jefferies Virtual Gene Therapy/Editing Summit on Thursday, October 1 st at 9:00 a.m. ET .
Additional Formats
Sep 09, 2020
- Early diagnosis through genetic testing may lead to improved long-term outcomes for patients with neurotransmitter disorders, including AADC deficiency - SOUTH PLAINFIELD, N.J. , Sept. 9, 2020 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today introduced a new program that provides
Additional Formats